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Placentaaccretareferstoanyabnormallyinvasiveplacentalimplantation.Diagnosisissuspectedpostpartumwithfaileddeliveryof
a retained placenta. Massive obstetrical hemorrhage is a known complication, often requiring peripartum hysterectomy. We report
a case of presumed placenta accreta in a patient following failed manual removal of a retained placenta. We describe an attempt
at conservative management with methotrexate in a stable patient desiring future fertility. Treatment was unsuccessful and led
to the development of a disseminated intrauterine infection complicated by a bowel obstruction, requiring both a hysterectomy
and small bowel resection. In hemodynamically stable patients, conservative management of placenta accreta may involve leaving
placental tissue in situ with subsequent administration of methotrexate. However, ongoing close observation is required to identify
complications.
1.Introduction
Placenta accreta is an obstetrical complication associated
with signiﬁcant maternal morbidity and mortality. It is
caused by a defect in the decidua basalis resulting in an
abnormally invasive placental implantation [1]. This dis-
ruption is often related to previous uterine scars, including
caesarean sections and prior uterine curettage [2]. Other risk
factors associated with placenta accreta are multiparity (>6
pregnancies); placenta previa; prior intrauterine infections;
elevated maternal serum alpha-fetoprotein; and maternal
age over 35 years [2–4]. Histologically, placenta accreta is
identiﬁed by trophoblastic invasion of the myometrium
in the absence of intervening decidua [1]. The spectrum
includes invasion of the superﬁcial myometrium (accreta),
invasion into deeper myometrial layers (increta), and inva-
sion through the serosa and/or adjacent pelvic organs
(percreta) [5].
Ideally, the diagnosis might be evaluated antenatally
in high-risk pregnancies and suspected using ultrasound
[1]. This could allow for predelivery planning to reduce
maternalmorbidity andmortality.Unfortunately,mostcases
are identiﬁed only at the time of delivery when forcible
attempts at manual removal of the placenta are unsuccessful
[6]. Severe postpartum hemorrhage may result and may
lead to complications such as massive transfusion of blood
products; DIC; acute renal failure; infectious morbidities;
ARDS; loss of fertility [1] .M o r t a l i t yi sa sh i g ha s7 %[ 7].
Traditionally, caesarean hysterectomy at the time of
delivery has been the preferred management strategy for
placenta accreta [1]. Not only does this approach preclude
future fertility, but it is also a procedure synonymous with
signiﬁcant perioperative risks [7]. For women who wish
to conserve their reproductive function, other treatment
options have been described. In some settings, uterine con-
servation (withtheplacenta leftinsitu)maybeanalternative
strategy [5–9]. Adjuvant therapy with methotrexate has also
been used to expedite resorption of placental tissue [6–8].
2. The Case
A 32-year-old multiparous woman (gravida 7, para 6)
presented to a nursing station in Arviat, Nunavut at 34 weeks
gestational age in preterm labour. The patient subsequently
delivered precipitously prior to transfer to a tertiary care2 Journal of Pregnancy
centre.Herobstetricalhistorywassigniﬁcantforsixprevious
vaginal deliveries and two neonatal deaths secondary to
an autosomal recessive metabolic disorder. She had been
transferred to a tertiary centre in Winnipeg twice during her
current pregnancy for episodes of antepartum hemorrhage.
At 19 weeks, she was admitted to hospital for observation
and was discharged home after 24 hours. At 32 weeks, she
was admitted again for vaginal bleeding. On this admission,
her hemoglobin was 78g/L. A subsequent fetal assessment
conﬁrmed an unremarkable right anterolateral placenta that
was clear of the internal os and an active fetus with a
biophysicalproﬁlescoreof8/8.Noevidenceofabruptionwas
noted. She was discharged home.
Following spontaneous vaginal delivery, the placenta
failed to deliver over the next eight hours. The patient was
transferred to a community hospital in northern Manitoba
formanualremoval.Uponarrival,shewashemodynamically
stable without signiﬁcant vaginal bleeding. The patient was
taken to the operating room to undergo manual removal of
the retained placenta. The surgeon was only able to remove
smallfragmentsoftissueastheremainderoftheplacentawas
densely adherent to the myometrium. Intraoperative vaginal
bleeding occurred and was managed with a combination
of vigorous fundal massage, uterine packing, oxytocin, and
carboprost. The bleeding settled over the following 18 hours,
at which point the packing was removed. She received
prophylactic intravenous antibiotics and three units of
packed red blood cells. On postpartum day 2, an abdominal
ultrasoundwasperformed.Alarge12cmsofttissuemasswas
visualized at the uterine fundus that was felt to be invading
the myometrium.
On postpartum day 3, only mild vaginal bleeding had
occurred, and the patient was transferred to a tertiary
centre in Winnipeg with a presumed diagnosis of placenta
accreta. Upon arrival, her serum βhCG was 16320IU/L.
The following day, she received a single dose of 75mg of
methotrexate intramuscularly and was started on a course
of prophylactic cephalexin. Management then continued as
an outpatient with twice-weekly visits to clinic to monitor
for infection and bleeding. By postpartum day 16, her serum
βhCG had decreased to 1447UI/L and her hemoglobin to
79g/L. Upon assessment in clinic that day, she described
ongoing mild-to-moderate vaginal bleeding and was found
to have an isolated temperature of 38.5
◦C. The patient was
admitted to hospital for 48 hours. Blood cultures were taken,
two units of packed red blood cells were transfused, and
oral cephalexin was continued. An abdominal ultrasound
(Figure 1(a)) revealed persistent retained placental tissue.
Over the next week, the patient was again followed
in an outpatient setting (Figure 1(b)). A repeat βhCG was
479UI/L. On postpartum day 26, she reported a ﬁve-day
history of nausea, vomiting, reduced oral intake, abdom-
inal pain with eating, and failure to pass stool or ﬂatus.
Vaginal bleeding remained unchanged. On examination,
she was found to have signiﬁcant abdominal distension
and tenderness on palpation. She was afebrile with a
heart rate of 100 beats per minute and blood pressure of
96/58. The patient was admitted for investigation. She had
evidence of leukocytosis (white blood cells 21.7 × 109/L),
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Figure 1: Transabdominal ultrasound image taken on postpartum
day 17. This view of the uterine fundus demonstrates signiﬁcant
persistence of retained placental tissue approximately two weeks
after methotrexate administration. Serum βhCG was 1571UI/L.
The distinction between the placental mass (dotted line) and
myometrium (asterisk) is shown. Transabdominal ultrasound
image taken on postpartum day 24. This view of the uterine fundus
shows signiﬁcant persistence of retained placental tissue approxi-
matelythreeweeksaftermethotrexateadministration.SerumβhCG
was 479UI/L. The distinction between the placental mass (dotted
line) and myometrium (asterisk) is depicted.
thrombocytosis (platelets 560 × 109/L), and pre-renal failure
(creatinine 140μmol/L, urea 12.6mmol/L). An abdominal
plain ﬁlm demonstrated dilated loops of bowel and multiple
air-ﬂuid levels consistent with a small bowel obstruction. At
this time, blood cultures from the previous admission had
grown Prevotella corporis.
The patient was admitted for hydration, bowel rest,
pain management, and intravenous antibiotics. Intravenous
cefoxitin 1g every eight hours was chosen based on the
blood culture sensitivities. A CT abdomen conﬁrmed a
mechanical small bowel obstruction with a possible adhe-
sion noted between the uterine fundus and small bowel
(Figure 2). Placental tissue was again noted at the fundus. In
consultationwiththegeneralsurgeryservice,theobstruction
was to be managed conservatively. A consultation was also
requested with a senior gynecologist regarding management
of the retained placental tissue. The prevailing consensusJournal of Pregnancy 3
Figure 2: CT scan of the patient’s abdomen on postpartum
day 27 demonstrating the uterus with the retained placenta was
demonstrated (arrow). The presence of dilated, ﬂuid ﬁlled loops of
smallbowelwithcollapseofthelargebowelconﬁrmedthediagnosis
of a mechanical small bowel obstruction. A possible adhesion was
noted between the uterine fundus and the bowel (not shown here).
was that an endomyometritis had occurred secondary to
the placenta accreta and had progressed to bacteremia,
peritonitis, and intestinal ileus. The patient was consented
for an elective dilatation and curettage to be carried out
within the next few days. She was received informed consent
with respecttopossible complications, including laparotomy
and hysterectomy.
On postpartum day 29, the patient was taken to the
operating room for a dilatation and curettage. During the
procedure, a uterine perforation identiﬁed as bowel was
pulled through the cervix with forceps. The surgeon pro-
ceeded to laparotomy. A large necrotic defect with purulent
material was noted at the uterine fundus. Swabs were taken
forcultureandsubsequentlygrewPrevotellaspecies.Further-
more, the small bowel and left ovary were adherent to the
uterus. Surgical management of the ﬁndings included a total
hysterectomy, in addition to an Intraoperative consultation
with a general surgeon for a small bowel resection with
primary reanastomosis. Blood loss was 100mL.
By the evening of postoperative day 0, the patient had
become increasingly tachycardic and hypotensive. Urine
output decreased dramatically, and signiﬁcant abdominal
distension was found. Serum hemoglobin decreased from
93g/L to 81g/L. Postoperative hemoperitoneum was diag-
nosed. She received volume resuscitation with crystalloid,
colloid, and packed red blood cells. The patient returned to
the operating room for an emergency exploratory laparo-
tomy. Upon entry, bleeding was noted from the right
infundibulopelvic pedicle and left vaginal cuﬀ angle. All
bleeding pedicles were reinforced, and good hemostasis was
achieved.
Postoperatively the patient did well. She received further
bowel rest with total parenteral nutrition until she was
consistently passing ﬂatus and able to tolerate oral intake. A
mild wound infection developed on postoperative day 4, and
antibiotic therapy was changed to oral amoxicillin/clavulin
based on culture sensitivities to cover Prevotella (blood), E.
coli (wound), and non-hemolytic streptococcus (wound).
The patient was ﬁnally discharged from hospital in good
condition on postoperative day 10. Pathology conﬁrmed the
presenceofnecroticandinfarctedvilloustissueattheuterine
fundus consistent with placenta accreta. Acute and chronic
serositisofthesmallbowelwasnoted.Incidentally,thecervix
was found to have high-grade dysplasia.
3. Discussion
The incidence of placenta accreta approximates 1 in 1000
deliveries and has been increasing largely due to the global
increase in caesarean deliveries. Patients at risk for abnormal
placentation should be assessed antenally by ultrasonogra-
phy, with or without adjunct magnetic resonance imaging if
indicated [1]. The women at the highest risk are those with
placenta previa in the current pregnancy and a history of
prior caesarean delivery.
Optimal management of abnormally invasive placenta-
tion remains unclear. Traditionally, primary hysterectomy
at the time of caesarean section has been the mainstay of
therapy particularly in cases where the diagnosis has been
discovered antenatally [10]. This procedure has been asso-
ciated with signiﬁcant maternal morbidity and mortality. In
a recent systematic review, emergency postpartum hysterec-
tomy was found to be associated with maternal morbidity
in 56% of cases and with a mortality rate of 3% [11]. In
addition to obvious loss of fertility, complications include
injury to the gastrointestinal or urinary tracts, infection,
as well as massive obstetrical hemorrhage and its sequelae
[6, 11]. Furthermore, it has been recognized that planned
caesareanhysterectomyisassociatedwithfewerperioperative
complications compared to emergent procedures [12].
Whenanextirpativeapproachisutilizedtoexcisethepla-
centa from the uterus, severe bleeding necessitating urgent
hysterectomy may occur [7]. This scenario is encountered
when placenta accreta is diagnosed peripartum following
failed removal of a retained placenta.
Several reports have described the use of more conser-
vative strategies aimed at preserving the uterus and main-
taining future fertility [5–9]. This approach involves leaving
the placental tissue in situ providing that the patient remains
hemodynamic stable, without life-threatening hemorrhage,
andwithadesireforongoingfertility.Presumingthediagno-
sis at placenta accreta can be anticipated, eﬀorts to minimize
bloodlossmaybeutilized.Thesemightincludehavingblood
products and uterotonic agents available for delivery; blood
cell saver technology; compression sutures; uterine packing;
selective arterial embolization and/or balloon occlusion; and
uterine and/or hypopgastric artery ligation [1]. Although
prenatal imaging may be useful, ultrasound ﬁndings sugges-
tive of placenta accreta may not always be appreciated. In
one review, only 44% of cases were suspected on the basis
of antenatal ultrasound [9].
Methotrexate has also been described an as adjuvant
therapy for the conservative management of placenta accreta
[1, 6–9]. It has been hypothesized that methotrexate acts4 Journal of Pregnancy
by inducing placental necrosis and expediting a more rapid
involution of the placenta [13]. This contradicts the belief
that methotrexate acts only on rapidly dividing cells, given
that trophoblast proliferation is not felt to occur at term
[14]. Thus, there is controversy as to the eﬀectiveness of
methotrexate as an adjuvant treatment. Also, there is a lack
ofconsensusregardingoptimaldosing,frequency,orrouteof
administration. In this particular case, a single dose of 50mg
per m2 of body surface area was used, similar to the protocol
used in the management of ectopic pregnancy at our centre.
In a recent review, conservative management was utilized
in 167 cases of placenta accreta/percreta. [9]. The failure
rate was 22% and hysterectomy, either primary or delayed,
was required mostly for severe hemorrhage. Severe maternal
morbidity, including one maternal death, occurred in 6% of
cases. The death was attributed to aplasia and nephrotoxicity
secondary to intraumbilical administration of methotrexate.
This case highlights the adverse eﬀects that may occur
following even a single dose of adjuvant methotrexate.
Another retrospective review of 60 cases of placenta
accreta found similar outcomes among women managed
conservatively with the placenta in situ w h e t h e ro rn o t
adjuvant treatments were used [6]. Of the twenty-six women
managed without the use of additional therapies, 22 (85%)
had a favourable outcome. In the remaining 4 cases, conser-
vative management failed, and a hysterectomy was required
either due to severe hemorrhage or infection. An additional
22 women received methotrexate. Treatment failed in 5
patients; thus, hysterectomy was avoided in 77% of cases.
Kayem et al. compare two strategies of management
in their centre over two diﬀerent time periods [7]. In the
ﬁrst time period, a policy of removing all placenta tissue
was employed (13 cases). In the second, the standard of
care changed to leaving the placenta in situ (20 cases). The
hysterectomy rates in the ﬁrst and second time periods were
85% and 15%, respectively. Most cases occurred in women
where the diagnosis was recognized at the time of delivery
and were subsequent to severe hemorrhage or infection.
Although conservative management of placenta accreta
appears to be successful at preventing hysterectomy in most
cases, there is still potential for morbidity. If such an
approach is used, intensive monitoring for complications
is required. Women may continue to be at risk for weeks
to months after delivery. Sentilhes et al. reported a median
period to delayed hysterectomy of 22 weeks [9].
Fever is a commonly reported complication. Most cases
are secondary to endomyometritis or ﬂorid sepsis; however,
fever may also represent an inﬂammatory response to
tissue necrosis in the absence of an infectious source [13].
Prophylactic broad-spectrum antibiotic therapy may reduce
the incidence of infectious morbidity [6–8]. In our case,
the patient developed Prevotella corporis bacteremia despite
the use of prophylactic antibiotics. Prevotella species are
anaerobic gram-negative bacilli that can be implicated in
puerperal infections [15]. Therapy must be adjusted based
on culture sensitivities as up to one third of strains may be
resistant to β-lactam antimicrobials [15].
Vaginal bleeding may also complicate management for
several months following delivery. In Timmermans’ review,
fever and vaginal bleeding each occurred in 35% of patients
and were the inciting factors leading to hysterectomy in all
but one (92%) of the patients with treatment failure [6].
Similarly, Sentilhes et al.reported delayedvaginal bleeding as
the reason for hysterectomy in 8 of the 36 treatment failures
(22%),whilesepsiswasimplicatedin7cases[9].Kayemetal.
describe a signiﬁcantly lower occurrence of disseminated
intravascular coagulopathy, presumably secondary to severe
hemorrhage, in women managed with the placenta in situ
(5%) compared to cases where the placental tissue was
removed (39%) [7].
Another controversy surrounding the use of methotrex-
ateinthemanagementofplacentaaccretahasbeentheutility
of monitoring serum βhCG. The prognostic implications
of decreasing βhCG levels following administration of
methotrexate are better described in the setting of ectopic
pregnancy. For placenta accrete, it is not clear whether
decreasing levels correlate with the rate of involution of
placental tissue. In one study, the serum βhCG levels
decreased with a half-life of 5.2 days in women managed by
leaving the placenta in situ and did not vary with the volume
of remaining tissue [16]. Another report described a half-
life of serum βhCG of 5.8 days in cases of retained placenta
managed with methotrexate [17].
4. Conclusion
We report a case of placenta accreta in a multiparous
patient that was conservatively managed with the placenta
in situ and adjuvant methotrexate. Although initially the
patientdidwell,shedevelopedsevereendomyometritisatthe
placental site that spread to involve the small bowel, a rare
complication not previously reported by other authors. The
conservative approach failed as a subsequent hysterectomy,
and bowel resection were required. Furthermore, despite
the signiﬁcant decrease in the serum βhCG levels, a large
placental mass persisted as evidenced by repeat ultrasound
examinations during her management.
This case depicts a common complication associated
with this approach to treatment of placenta accreta as well
as the need for intensive monitoring. Despite the use of pro-
phylacticantibiotics,ourpatientdevelopedendomyometritis
and bacteremia. Nonetheless, experience in the literature
suggests that conservative management of placenta accreta
may be valid in select patients with favourable outcomes.
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